The effectiveness of ablative therapies for hepatocellular carcinoma (HCC) is evaluated based on a combination of several factors, which can include imaging studies, tumor response criteria (such as mRECIST), tumor marker levels (such as AFP), recurrence rates, and patient outcomes (including overall survival, progression‐free survival, and quality of life).13 This evidence concerns the gene AFP and hepatocellular carcinoma.